Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid FeaturesBradley A. McGregor, Toni K. Choueiri, John A. Steinharter et al.|Journal of Clinical Oncology|2019Cited by 147
Table S1 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J. Kwiatkowski, Sabina Signoretti, Toni K. Choueiri et al.|Unknown|2023Cited by 0
Table S1 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J. Kwiatkowski, Sabina Signoretti, Toni K. Choueiri et al.|Unknown|2023Cited by 0
Table S3 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J. Kwiatkowski, Sabina Signoretti, Toni K. Choueiri et al.|Unknown|2023Cited by 0